


AMENDMENTS TO THE CLAIMS

Applicant has submitted a new complete claim set. This listing of claims will replace all prior versions and listings of claims in the application:

1. (original) A compound of the formula:



wherein,

R₁ is alkyl, aryl, or heterocyclyl;

R₂ is H, alkyl, aryl, heterocyclyl, OR₃, or N(R₃)₂;

R₃ is H, alkyl, aryl, or heterocyclyl;

R₄ is H, CN, halogen, CF₃, CO₂R₃, or C(O)N(R₃)₂;

X is S, SO₂, O, or NR₃; and

Y is S, O, or NR₃.

2. (original) The compound of claim 1, wherein

R₁ is alkyl, aryl, or heterocyclyl;

R₂ is H, aryl, heterocyclyl, OR₃, or N(R₃)₂;

R₃ is aryl or heterocyclyl;

R₄ is H, CN, halogen, CF₃, or C(O)N(R₃)₂;

X is S, SO₂, or O; and

Y is S or O.

3. (original) The compound of claim 1, wherein

R₁ is alkyl, aryl, or heterocyclyl;

R₂ is H, OR₃, or N(R₃)₂;


R₃ is aryl or heterocyclyl;

R₄ is H, CN, F, Cl, Br, or CF₃;

X is S; and

Y is S.

4. (original) The compound of claim 1, wherein the compound is represented by the formula:



5. (currently amended) A pharmaceutical composition comprising an effective amount of a compound of claim 1, 2, 3, or 4, and a pharmaceutically acceptable carrier.

6-11. (canceled)

12. (original) The pharmaceutical composition of claim 5, further comprising an antigen.

13. (original) The pharmaceutical composition of claim 12, wherein the antigen is a cancer antigen.

14. (original) The pharmaceutical composition of claim 12, wherein the antigen is a viral antigen, a bacterial antigen, a fungal antigen or a parasitic antigen.

15-23. (canceled)

24. (currently amended) A method of modulating an immune response in a subject, comprising: administering to a subject in need of such immune modulation an amount of a compound of claim[[s]] 1, 2, 3, or 4, effective to enhance the subjects immune response to an antigen.

25-28. (canceled)

29. (currently amended) [[A]] The method of claim 24 wherein the subject is a ~~for treating a subject~~ having or at risk of having a cancer expressing a cancer antigen, ~~comprising administering to the subject a therapeutically effective amount of a compound of claims 1, 2, 3, or 4.~~

30-44. (canceled)

45. (currently amended) [[A]] The method of claim 24 wherein the subject is a ~~for treating a subject~~ having or at risk of having an infectious disease, ~~comprising administering to the subject a therapeutically effective amount of a compound of claims 1, 2, 3, or 4.~~

46-67. (canceled)

68. (currently amended) A method of enhancing MHC Class II catalyzed peptide exchange comprising contacting a cell bearing a MHC Class II molecule with a compound of claim[[s]] 1, 2, 3, or 4, in the presence of a peptide that binds MHC class II .

69-100. (canceled)

101. (original) An assay comprising:

providing isolated MHC class II molecule bound to CLIP;

contacting the isolated MHC class II molecule with a test compound;

contacting the isolated MHC class II molecule with HLA-DM and with a peptide that binds the isolated MHC class II molecule;

measuring the kinetics of binding of the peptide to the isolated MHC class II molecule; and

determining whether the test compound enhances binding of the peptide to the isolated MHC class II molecule as compared to a control.

102. (original) The assay of claim 101, wherein the peptide is fluorescently labeled.

103-109. (canceled)

110. (original) A kit comprising:

a first container containing isolated MHC class II bound to CLIP; and

a second container containing a peptide that binds the isolated MHC class II.

111. (original) The kit of claim 110 further comprising a third container containing HLA-DM.

112. (original) The kit as claimed in claim 110, wherein the peptide is fluorescently labeled.

113. (canceled)